Innate Pharma SA Finance Costs
Innate Pharma SA (IPHA) reported Finance Costs of EUR 3.12 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:FinanceCosts · last filed 2026-04-01
| Period end | Finance Costs 6 month | Finance Costs 12 month |
|---|---|---|
| 2025-12-31 | 3.12M EUR 20-F · filed 2026-04-01 | |
| 2025-06-30 | 2.80M EUR 6-K · filed 2025-09-17 | |
| 2024-12-31 | 3.98M EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | 2.06M EUR 6-K · filed 2025-09-17 | |
| 2023-12-31 | 1.83M EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 966.00K EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | 5.32M EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 6.17M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | 4.00M EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | 1.78M EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | 6.76M EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | 4.43M EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | 4.98M EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 8.43M EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 10.54M EUR 20-F · filed 2020-04-24 |